Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Inventory: 2021-2025

Historic Inventory for Rhythm Pharmaceuticals (RYTM) over the last 3 years, with Sep 2025 value amounting to $22.1 million.

  • Rhythm Pharmaceuticals' Inventory rose 59.10% to $22.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.1 million, marking a year-over-year increase of 59.10%. This contributed to the annual value of $18.7 million for FY2024, which is 117.31% up from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Inventory is $22.1 million, which was up 17.14% from $18.9 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Inventory peaked at $22.1 million during Q3 2025, and registered a low of $111,000 during Q4 2021.
  • In the last 3 years, Rhythm Pharmaceuticals' Inventory had a median value of $12.0 million in 2024 and averaged $12.9 million.
  • Data for Rhythm Pharmaceuticals' Inventory shows a peak YoY soared of 2,527.93% (in 2022) over the last 5 years.
  • Over the past 5 years, Rhythm Pharmaceuticals' Inventory (Quarterly) stood at $111,000 in 2021, then spiked by 2,527.93% to $2.9 million in 2022, then soared by 195.65% to $8.6 million in 2023, then soared by 117.31% to $18.7 million in 2024, then skyrocketed by 59.10% to $22.1 million in 2025.
  • Its last three reported values are $22.1 million in Q3 2025, $18.9 million for Q2 2025, and $19.3 million during Q1 2025.